What do federal funding cuts mean for MS researchers and those living with the disease? Then, should you kiss your dentist ...

Neurodegeneration in multiple sclerosis can be monitored via OCT of inner retinal layers in the macular region, according to ...

The patent comes months after Immunic Therapeutics announced CALLIPER study results, which tested vidofludimus calcium in ...

The firm's commercialization push is fueled by $35.6 million from a recent Series C financing and a $15.5 million ...

Ocrevus rapidly depletes immune B-cells in people with MS, but ongoing treatment also leads to changes in immune T-cells, a ...

Great Place To Work® and Fortune magazine have selected the International Multiple Sclerosis Management Practice (IMSMP) for the 2025 Fortune Best Workplaces in Health Care™ List. This recognition ...

BRIUMVI is indicated in the U.S. for the treatment of adults with RMS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease and in the EU and ...

Researchers have created an assessment to identify MS patients who have cognitive impairment but few mobility issues, a newly recognized MS subtype.

IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and ...

Discover how biomarkers like neurofilament light chain and glial fibrillary acidic protein enhance personalized care for ...

HealthDay News — Nearly 80 percent of neurologists prescribing multiple sclerosis (MS) drugs receive payments from industry, according to a study published online Aug. 26 in BMJ Open.

Immunic receives US patent protecting vidofludimus calcium's dose strengths in progressive multiple sclerosis: New York Wednesday, September 10, 2025, 13:00 Hrs [IST] Immunic, Inc ...